New Velocity Vials Technology Platform to Expand Industry Partnerships
This will allow industry leaders to make and sell the product, in addition to providing more choice to pharma and biotech companies.
Corning Pharmaceutical Technologies announced its Velocity Vials Technology Platform on June 8, 2023 to increase access to Corning’s Velocity Vial technology. This will allow industry leaders to make and sell the product, in addition to providing more choice to pharma and biotech companies.
According to the company press release, Corning will expand its manufacturing footprint, localize its supply chains, and enable the purchase of Velocity Vials through a network of selling partners. The new partnership with Gerresheimer AG will combine Gerresheimer’s extensive glass converting expertise with Corning’s innovative external vial coating technology, which helps with co-manufacturing and selling Velocity Vials.
Shortly after, SGD Pharma joined and announced a joint venture with Corning that includes the opening of a new glass tubing facility and expanded access to Velocity Vial technology in India. Further, Velocity Vials are important to the global distribution of essential vaccines and medications during the COVID-19 pandemic, according to the company.
“We are starting to see a paradigm shift in the pharmaceutical primary-packing industry, where coated vials are becoming the new industry standard,” said Brendan Mosher, vice president and general manager, Corning Pharmaceutical Technologies, in a press release. “Velocity Vials have demonstrated immediate benefits for our customers. The adoption of the technology by leading pharmaceutical-packaging providers is yet another proof point of this evolution.”
Velocity Vials can improve filling-line efficiency by up to 50%, which lowers costs while also improving the quality. It can also reduce the likelihood of damage that leads to cracks, breaks, and cosmetic defects. The vials are made with Type 1 borosilicate glass and conform to ISO standard dimensions, and they can be dropped-in to existing operations with no significant changes or reporting to regulatory authorities, according to the company press release.
Source: Corning
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
